Latest papers

Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an increased risk for recurrence.

Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy.

Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.

Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease.

Rapid engraftment at a cost?

Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation.

Analysis of clinical outcome and survival in pediatric patients undergoing extracorporeal photopheresis for the treatment of steroid-refractory GVHD.

Current insights into ocular graft-versus-host disease.

CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-γ pathway.

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation.

Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in mice.

Effects of pravastatin on murine chronic graft-versus-host disease.

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation.

Late complications in blood and marrow transplant survivors.

A crucial role for host APCs in the induction of donor CD4+CD25+ regulatory T cell-mediated suppression of experimental graft-versus-host disease.

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

[Rationale for the use of extracorporeal photochemotherapy in children].